The evaluation of the efficacy and safety of the humanized anti-PD-1 antibody camrelizumab in combination with the VEGFR tyrosine kinase inhibitor apatinib in advanced MM showed an ORR of 42.9%, a DCR of 82.1%, and a median PFS of 8.05 months [193,194]. This evidence concerns the gene KDR and Miyoshi myopathy.